Condition: Cholesterol

ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU_MDCO-PCS-17-01 (CKJX839B12301)). The study aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk of heart attacks and strokes in people who have already had one of these conditions, or who have had an operation or procedure to treat blocked arteries.

Location(s): Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Cholesterol, Heart Disease

This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with very-high risk for CVD on a stable diet and oral LDL-C lowering drug therapy.

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Cholesterol, Heart Disease

This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a stable diet and oral LDL-C lowering drug therapy

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Cholesterol, Heart Disease

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy.

Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine

Condition: Cholesterol, Heart Disease